Crescita Announces Licensing Agreement for Pliaglis; in China
The Pharma Data
NOVEMBER 4, 2020
As part of the License Agreement, Crescita will receive an upfront payment in cash of US$125,000 and will be eligible for regulatory and sales milestones of up to US$1.0 The formulation contains a eutectic mixture of 7% lidocaine and 7% tetracaine that utilizes the Company’s proprietary phase-changing topical cream Peel technology.
40 
Let's personalize your content